↓ Skip to main content

Cognitive remission: a novel objective for the treatment of major depression?

Overview of attention for article published in BMC Medicine, January 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
3 tweeters
facebook
4 Facebook pages
reddit
2 Redditors

Citations

dimensions_citation
70 Dimensions

Readers on

mendeley
224 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cognitive remission: a novel objective for the treatment of major depression?
Published in
BMC Medicine, January 2016
DOI 10.1186/s12916-016-0560-3
Pubmed ID
Authors

Beatrice Bortolato, Kamilla W. Miskowiak, Cristiano A. Köhler, Michael Maes, Brisa S. Fernandes, Michael Berk, André F. Carvalho

Abstract

Cognitive dysfunction in major depressive disorder (MDD) encompasses several domains, including but not limited to executive function, verbal memory, and attention. Furthermore, cognitive dysfunction is a frequent residual manifestation in depression and may persist during the remitted phase. Cognitive deficits may also impede functional recovery, including workforce performance, in patients with MDD. The overarching aims of this opinion article are to critically evaluate the effects of available antidepressants as well as novel therapeutic targets on neurocognitive dysfunction in MDD. Conventional antidepressant drugs mitigate cognitive dysfunction in some people with MDD. However, a significant proportion of MDD patients continue to experience significant cognitive impairment. Two multicenter randomized controlled trials (RCTs) reported that vortioxetine, a multimodal antidepressant, has significant precognitive effects in MDD unrelated to mood improvement. Lisdexamfetamine dimesylate was shown to alleviate executive dysfunction in an RCT of adults after full or partial remission of MDD. Preliminary evidence also indicates that erythropoietin may alleviate cognitive dysfunction in MDD. Several other novel agents may be repurposed as cognitive enhancers for MDD treatment, including minocycline, insulin, antidiabetic agents, angiotensin-converting enzyme inhibitors, S-adenosyl methionine, acetyl-L-carnitine, alpha lipoic acid, omega-3 fatty acids, melatonin, modafinil, galantamine, scopolamine, N-acetylcysteine, curcumin, statins, and coenzyme Q10. The management of cognitive dysfunction remains an unmet need in the treatment of MDD. However, it is hoped that the development of novel therapeutic targets will contribute to 'cognitive remission', which may aid functional recovery in MDD.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 224 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 2 <1%
United States 2 <1%
Unknown 220 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 35 16%
Researcher 35 16%
Student > Bachelor 33 15%
Student > Ph. D. Student 27 12%
Student > Doctoral Student 16 7%
Other 52 23%
Unknown 26 12%
Readers by discipline Count As %
Medicine and Dentistry 62 28%
Psychology 51 23%
Neuroscience 25 11%
Agricultural and Biological Sciences 11 5%
Biochemistry, Genetics and Molecular Biology 8 4%
Other 29 13%
Unknown 38 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 November 2016.
All research outputs
#795,839
of 14,002,013 outputs
Outputs from BMC Medicine
#657
of 2,198 outputs
Outputs of similar age
#23,695
of 338,236 outputs
Outputs of similar age from BMC Medicine
#1
of 1 outputs
Altmetric has tracked 14,002,013 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,198 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.2. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,236 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them